Table 2 Comparison of clinical, laboratory and radiological data among cases and controls

Age (years)

6.5 ± 3.05

6.7 ± 2.05

1.2

0.11

(3.2 -10.9)

(3.5-10.8)

Sex , n(%)

Males

27(54 %)

28 (56 %)

1.11

0.23

Females

23(46 %)

22(44 %)

Height SDS

-3.12 ± 0.2

+1.04 ± 0.5

19.88

 <0.001***

(-2.15- -4.21)

(+0.99 - +1.65)

GV after Zn (cm/3 months)

0.55 ± 0.1

0.61 ± 0.1

0.82

0.11

(0.1-2.23)

(0.2-3.13)

GV SDS

+1.01 ± 0.2

+1.21 ± 0.1

1.3

0.15

(-0.5 - +2.11)

(-0.3 - +2.31)

Weight SDS

-1.88 ± 0.62

-1.02 ± 0.71

1.7

0.2

(-2.01 - +0.55)

(-1.20 - +1.45)

BMI (kg/m2)

16.41 ± 1.56

17.51 ± 0.52

1.0

0.3

(14.33-20.12)

(14.33-20.12)

BMI SDS

-1.77 ± 0.41

-1.02 ± 0.31

1.99

0.082

(-2.10- -0.78)

(-1.30 - +0.23)

Serum Zn (μg/dl)

56.76 ± 7.90

136.70 ± 8.10

22.5

<0.001***

(37.52-93.11)

(123.17-149.50)

Peak GH after insulin stimulation (ng/ml)

10.65 ± 2.01

14.25 ± 3.01

6.50

0.04*

(7.61-13.20)

(10.91-18.30)

Peak GH after clonidine stimulation (ng/ml)

11.14 ± 1.41

15.24 ± 2.11

6.81

0.041*

(6.92-14.11)

(11.12-19.21)

IGF-1 (ng/ml)

96.72 ± 11.5

286.62 ± 12.5

12.86 

<0.001***

(36.52-115.69)

(198.72-325.19)

IGF-1 SDS

-2.46 ± 0.11

+1.46 ± 0.21

17.66

<0.001***

(-3.22- +0.55)

(+0.89 - +1.85)

IGFBP-3 (ng/ml)

2436.12 ± 392

3936.22 ± 194

15.12

<0.001***

(1195.45-3898.15)

(3721.45-4498.15)

-BA (years)

3.7 ± 1.05

6.8 ± 1.6

6.11

0.020*

(1.81-9.25)

(3.31-11.25)

-BA SDS

-1.75 ± 1.14

+0.85 ± 1.20

13.24

<0.001***

(-2.44 - +0.22)

(+1.04 - +0.22)